Sec Form 3 Filing - ARCH Venture Partners X, LLC @ Erasca, Inc. - 2021-07-15

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 3
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
ARCH Venture Partners X, LLC
2. Issuer Name and Ticker or Trading Symbol
Erasca, Inc. [ ERAS]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
8755 W. HIGGINS ROAD, SUITE 1025,
3. Date of Earliest Transaction (MM/DD/YY)
07/15/2021
(Street)
CHICAGO, IL60631
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 1,750,000 I By ARCH Venture Fund X, L.P. ( 2 ) ( 3 )
Series A Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 1,750,000 I By ARCH Venture Fund X Overage, L.P. ( 2 ) ( 3 )
Series B-1 Preferred Stock $ 0 ( 4 ) ( 4 ) Common Stock 2,833,333 I By ARCH Venture Fund X, L.P. ( 2 ) ( 3 )
Series B-2 Preferred Stock $ 0 ( 4 ) ( 4 ) Common Stock 944,444 I By ARCH Venture Fund X Overage, L.P. ( 2 ) ( 3 )
Series B-1 Preferred Stock $ 0 ( 4 ) ( 4 ) Common Stock 2,833,333 I By ARCH Venture Fund X Overage, L.P. ( 2 )
Series B-2 Preferred Stock $ 0 ( 4 ) ( 4 ) Common Stock 944,444 I By ARCH Venture Fund X Overage, L.P. ( 2 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ARCH Venture Partners X, LLC
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
ARCH Venture Fund X, L.P.
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
ARCH Venture Fund X Overage, L.P.
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
ARCH Venture Partners X, L.P.
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
60631, IL
X
ARCH Venture Partners X Overage, L.P.
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
NELSEN ROBERT
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
CRANDELL KEITH
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
Burow Kristina
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
GILLIS STEVEN
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO, IL60631
X
Signatures
/s/ ARCH Venture Fund X, L.P., By: ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ ARCH Venture Fund X Overage, L.P., By: ARCH Venture Partners X Overage, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ ARCH Venture Partners X Overage, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ Robert Nelsen, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ Keith Crandell, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ Kristina Burow, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
/s/ Steven Gillis, By: Mark McDonnell, attorney-in-fact 07/15/2021
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The shares of Series A Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1.2-for-1. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1.2-for-1. The Series A Preferred Stock has no expiration date.
( 2 )ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage.
( 3 )(Continued from Footnote 2) AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to any pecuniary interest therein.
( 4 )The shares of Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1.2-for-1. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1.2-for-1. The Series B Preferred Stock has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.